[How to act when an alpha-blocker is associated with a potent inhibitor of CYP3A4].

  title={[How to act when an alpha-blocker is associated with a potent inhibitor of CYP3A4].},
  author={Nadia Bensalah and Stephan Garcia and Fateema Rose and Pierrick Bedouch and Ornella Conort and Michel Juste and Renaud Roubille and Beno{\^i}t Allenet and Michel Tod and Bruno Charpiat},
  journal={Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie},
  volume={27 5},
OBJECTIVE Combination of alpha-blockers with potent CYP3A4 inhibitors is either contra-indicated or not recommended. We searched data supporting this classification and guiding prescribers when such an interaction occurs. METHODS We analyzed reports published by the French agency for drug safety, reference books and performed search in databases of pharmacokinetics studies and case or case series related with these interactions. RESULTS The classification of the potential severity of these… CONTINUE READING

Topics from this paper.


Publications referenced by this paper.

The risk of fall and fracture with the initiation of a prostate - selective  antagonist : a population based cohort study

B Welk, E McArthur, +3 authors YJ Hwang
  • BMJ
  • 2015

Risk of hypotension with concomitant use of calcium-channel blockers and macrolide antibiotics.

  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2012